Mission Therapeutics to attend the Michael J. Fox Foundation’s 14th Annual Parkinson’s Disease Therapeutics Conference

CAMBRIDGE, UK – 11 October 2022 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), today announced that Dr Paul Thompson, Chief Scientific Officer, and Dr Suhail Nurbhai, Chief Medical Officer, will attend the 14th Annual Parkinson’s Disease Conference on 13 October 2022 in New York.

The Parkinson’s Disease Therapeutics Conference is the only conference globally that focuses exclusively on Parkinson’s disease drug development, providing an unmatched platform for industry leaders to share exciting new and unpublished data from the field. Mission will join over 300 research and business professionals in attending poster and speaker presentations.

– ENDS –


Mission Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel: +44 (0)1223 607 340 
Instinctif Partners
Melanie Toyne-Sewell / Katie Duffell/ Jonjo Cordey
Tel: +44 (0) 20 7457 2013 


About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Mission has strong links with key academic and research centers, including Prof. Steve Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company also has secured major industry partnerships, including its collaboration with AbbVie in November 2018, for the research and preclinical development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease. The Company is managed by a team with broad international, commercial and clinical-science experience.

To date the Company has received £73 million / $101 million in funding and its investors comprise blue chip institutional and corporate investors including: Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group and Rosetta Capital. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

For more information, please visit our website, www.missiontherapeutics.com, or follow us on Twitter or LinkedIn.